Proteome Sciences PLC on Friday said it won a contract from an unnamed US biopharmaceutical company to use Proteome’s mass spectrometry services.

The protein-focused drug development services provider said this was for analysing samples for an ongoing clinical trial by the unnamed company.

Proteome said the deal is worth over £500,000 to the company. The project will be provided utilising the Good Clinical Laboratory Practice accreditation obtained by Proteome Sciences specifically for this type of project.

It expects that a ‘good proportion’ of the work should be completed this year.

Shares in Proteome surged 31% to 4.59 pence each in London on Friday morning.

‘We have experienced good customer interest in our services in the first quarter reflected by the considerable increase in customer contact and quotations across a broad range of projects. In this contract the client selected our targeted assay workflows with GCLP compliance as a quality standard specifically to monitor the performance of their investigational drug in their clinical trial,’ said Proteome Chief Commercial Officer Richard Dennis.

‘We expect the increased levels of interest in our services activities to continue through 2024 and look forward to further clinical trial projects.’

Copyright 2024 Alliance News Ltd. All Rights Reserved.